Actelion and Czech PrimeCella.s view production in Belarus

7 June 2011

An official representative of the Belarus State Committee on Science and Technology said recently that Swiss biotech firm Actelion (SIX: ATLN) and PrimeCella.s of the Czech Republic are considering setting up manufacturing of the former’s drugs in Belarus.

According to Richard Kraulets, head of Actelion Pharmaceuticals Central and Eastern Europe, Middle East and Africa, Belarus can be considered as one of the most promising markets for the company’s further development in the coming years, taking into account its recent entry into the Customs Union with Russia and Kazakhstan.

The volume of investments and potential production capacities of the projected facility were not disclosed. According to Belarus analysts, if everything goes ahead, the new plant will probably specialize in the production of certain innovative drugs for the treatment of pulmonary hypertension developed by Actelion, among which are Tracleer (bosentan), Veletri (epoprostenol) and Ventavis (iloprost).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK